Intelligence · Clinical pipeline
Oncology · Phase III
Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- AstraZeneca 75 programs
- Chinese Academy of 70 programs
- HOFFMANN-LA ROCHE 68 programs
- MSD Merck Sharp 56 programs
- First People's Hospital 53 programs
- Ningbo Cancer Hospital 44 programs
- United Therapeutics Europe 43 programs
- Anaxis Pharma 37 programs
- AstraZeneca 37 programs
- Novartis India 32 programs
- George Institute for 29 programs
- Takeda 28 programs
Pipeline programs
-
IRINOTECAN
COLLEGIUM PHARMACEUTICAL, INC
Gastric Carcinoma
1 trial -
IRINOTECAN for Middle or low locally advanced resectable rectal carcinoma
Pari Pharma GmbH
Middle or low locally advanced resectable rectal carcinoma
1 trial -
IRST204.07
Istituto Gentili S.r.l.
Acute myeloid leukemia
1 trial -
ISIS 3521
IONIS PHARMACEUTICALS INC
Lung Cancer
1 trial -
ISRCTN12053408
Ningbo Cancer Hospital
Intermediate stage Hepatocellular carcinoma
1 trial -
IT-03
INTENSITY THERAPEUTICS, INC.
liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma
1 trial -
Ibrutinib
Janssen Cilag International NV
Chronic Lymphocytic Leukemia
1 trial -
Ibrutinib hard capsule for oral use, Ibrutinib
AbbVie Deutschland GmbH & Co. KG
Follicular Lymphoma
1 trial -
Imatinib
United Therapeutics Europe Ltd
Myeloid Leukemia, Chronic, Chronic Phase
1 trial -
Imatinib Mesylate Tablets, 400 mg
Amneal Pharma Europe Ltd
Chronic Myeloid Leukemia
1 trial -
Imiquimod 5% cream
Grace Therapeutics
Superficial Basal Cell Carcinoma
1 trial -
Immunonutrition （Su yusu)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastrointestinal Tumors
1 trial -
Individualized Elective Neck Irradiation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Induction Chemotherapy
The First People's Hospital of Lianyungang
Locally Advanced Nasopharyngeal Carcinoma
1 trial -
Infigratinib
BridgeBio Oncology Therapeutics
Upper Tract Urothelial Carcinomas
1 trial -
Intermediate-dose Cytarabine in Combination with Venetoclax
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (AML)
1 trial -
Intrarosa 6.5 mg pessary
Istituto Gentili S.r.l.
Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).
1 trial -
Investigator's choice of Chemotherapy
Zentalis Pharmaceuticals
Ovarian Cancer
1 trial -
Investigators choice of SoC
Novartis Pharmaceuticals
Prostate Cancer
1 trial -
Iomab-B
Actinium Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
Ipilimumab
Bristol-Myers Squibb
Melanoma
1 trial -
Irinotecan HCl-trihydraat Accord /ml concentr...
Disc Medicine
Non-metastatic resectable pancreatic cancer
1 trial -
Irinotecan HCl-trihydraat Fresenius Kabi /ml
Disc Medicine
non-metastatic (borderline) resectable pancreatic cancer
1 trial -
Irinotecan liposome、5-Fluorouracil、Leucovorin
Jian Li
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
1 trial -
Ivonescimab 10 mg/kg
Summit Therapeutics
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
1 trial -
Ivonescimab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
2 trials -
Ixabepilone + Capecitabine
Semnur Pharmaceuticals
Breast Cancer
1 trial -
J2G-MC-JZJB
Eli Lilly Co.
RET-Mutant Medullary Thyroid Cancer
1 trial -
J2G-MC-JZJC
Eli Lilly Co.
Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
1 trial -
J2J-OX-JZLC
Eli Lilly Co.
Breast Cancer
1 trial -
J3M-MC-JZQB
Eli Lilly Co.
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cancer
1 trial -
J3M-MC-JZQH
Eli Lilly Co.
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
1 trial -
J4G-MC-JZVD
Eli Lilly Co.
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
1 trial -
J5E-MC-JZXB
Eli Lilly Co.
Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Neoplasm Metastasis
1 trial -
J6M-MC-JSGD
Eli Lilly Co.
Neoplasm Metastasis, Breast Neoplasms
1 trial -
JDQ443
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
JEVTANA 60 mg concentrate and solvent for solution for infusion.
Ningbo Cancer Hospital
Patients with localized prostate cancer and high-risk features of relapse.
1 trial -
JNJ-54767414
Janssen-Cilag International N.V.
Precancerous form of blood cancer in the bone marrow
1 trial -
JNJ-56021927
Ningbo Cancer Hospital
High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.
1 trial -
JNJ-90301900 (NBTXR3)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Carcinoma, Squamous Cell
1 trial -
JPB898 (Induction and Maintenance)
Sandoz Pty Ltd
Melanoma
1 trial -
JS001
Shanghai University of Traditional Chinese Medicine
Triple-Negative Breast Cancer
1 trial -
JZP598-302
Jazz Pharmaceuticals Ireland Limited
BTC - Biliary Tract Cancer
1 trial -
JZP598-303
Jazz Pharmaceuticals Ireland Limited
Metastatic HER2-positive breast cancer
1 trial -
KER-050-D301
Takeda
myelodysplastic neoplasms/syndromes (MDS)
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion
Ningbo Cancer Hospital
High risk resected melanoma.
1 trial -
KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion
Ningbo Cancer Hospital
Uveal Melanoma
1 trial -
KO-MEN-017
Kura Oncology
NPM1-m and KMT2A-r Acute Myeloid Leukemia
1 trial
Frequently asked questions
How many oncology Phase III programs exist?
1,266 programs match both the therapeutic area and stage filters in our published index.